Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease

Inclusion Criteria: * 18 and above years of age inclusive, at the time of signing the informed consent. * Subjects with suspected ILD listed for TBCB for clinical reasons following review by the ILD services at University College London Hospitals (UCLH) in whom diagnosis has remained unclear following radiological and clinical assessment. * A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied, may be included only if the investigator in consultation with the Medical Monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. * Male or Female. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions. Exclusion Criteria: * Subjects who have a known drug allergy or other contra-indication to ipratropium bromide. * Known hypersensitivity to atropine or ipratropium bromide or any other known drug allergies that, in the opinion of the investigator or GlaxoSmithKline (GSK) Medical Monitor, contraindicates their participation. * As a result of the medical history, physical examination or screening investigations, the physician responsible considers the subject unfit for the study. * The subject is unable or unwilling to perform study assessments and procedures correctly. * Subjects with a recognized co-existing respiratory disorder (other than ILD) that in the opinion of the investigator would confound the study outcomes.